Biopharma & Life Sciences
Syndax Pharmaceuticals Executive Compensation (FY25)
SNDX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (DEF 14A): April 30, 2026
219 figures on this page: 215 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Michael Metzger, Chief Executive Officer, received $7,089,213 in total compensation for fiscal 2025, and Metzger's total was 8.0% lower than the $7,707,176 reported for fiscal 2024. The company reported a chief executive pay ratio of 19:1 for fiscal 2025, against median employee compensation of $383,252. The say-on-pay proposal drew 94.1% of votes cast including abstentions in favor at the meeting held May 14, 2025 for fiscal 2024. Companies named in the disclosed peer group include Agios Pharmaceuticals, Inc., Amicus Therapeutics, Apellis Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Bicycle Therapeutics plc, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Metzger: $7,707,176 → $7,089,213 (8.0% lower)
Say-on-pay support: 73.8% → 94.1% (20.3 points higher)
CEO pay ratio: 22:1 → 19:1 (13.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Syndax Pharmaceuticals' chief executive and what were they paid?
Michael Metzger, Chief Executive Officer, received $7,089,213 in total compensation for fiscal 2025. Metzger's total was 8.0% lower than the $7,707,176 reported for fiscal 2024.
What was Syndax Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 94.1% of votes cast including abstentions in favor at the meeting held May 14, 2025 for fiscal 2024.
Which companies are in Syndax Pharmaceuticals' peer group?
Companies named in the disclosed peer group include Agios Pharmaceuticals, Inc., Amicus Therapeutics, Apellis Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Bicycle Therapeutics plc, among others.
What is Syndax Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 19:1 for fiscal 2025, against median employee compensation of $383,252.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Metzger President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Keith Goldan Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Luke Albrecht General Counsel and Secretary | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Metzger President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Steve Closter Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Keith Goldan Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Luke Albrecht General Counsel | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Metzger Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Nick Botwood Head of Research and Development, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Keith Goldan Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Luke Albrecht General Counsel and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Steve Closter Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Keith A. Goldan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Keith A. Goldan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Keith A. Goldan | PSA | ◇ | — | — | ◇ | — | — | ◇ |
| Luke J. Albrecht | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Luke J. Albrecht | PSA | ◇ | — | — | ◇ | — | — | ◇ |
| Luke J. Albrecht | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael A. Metzger | PSA | ◇ | — | — | ◇ | — | — | ◇ |
| Michael A. Metzger | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael A. Metzger | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nick Botwood | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Nick Botwood | PSA | ◇ | — | — | ◇ | — | — | ◇ |
| Steve Closter | PSA | ◇ | — | — | ◇ | — | — | ◇ |
| Steve Closter | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Steve Closter | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Luke Albrecht | Option | ◇ | — | ◇ | 2/7/2034 |
| Option | ◇ | — | ◇ | 5/1/2035 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/5/2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/2/2033 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| Steve Closter | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 3/18/2034 | |
| Option | ◇ | — | ◇ | 2/5/2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Michael Metzger | Option | ◇ | — | ◇ | 2/7/2034 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| Option | ◇ | — | ◇ | 2/2/2033 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/5/2035 | |
| Keith Goldan | Option | ◇ | — | ◇ | 2/7/2034 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/2/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/13/2032 | |
| Option | ◇ | — | ◇ | 2/5/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Dennis G. Podlesak Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Keith A. Katkin | ◇ | ◇ | — | — | — | — | ◇ |
Pierre Legault | ◇ | ◇ | — | — | — | — | ◇ |
Jennifer Jarrett | ◇ | ◇ | — | — | — | — | ◇ |
Martin H. Huber, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Aleksandra Rizo, M.D., Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Michael A. Metzger served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee member | ◇ |
| Compensation committee member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agios Pharmaceuticals, Inc. AGIO
- Amicus Therapeutics FOLD
- Apellis Pharmaceuticals, Inc. APLS
- Arcus Biosciences, Inc. RCUS
- Bicycle Therapeutics plc BCYC
- Blueprint Medicines Corporation BPMC
- Catalyst Pharmaceuticals, Inc. CPRX
- Day One Biopharmaceuticals DAWN
- Deciphera Pharmaceuticals DCPH
- Exelixis, Inc. EXEL
- Geron Corporation GERN
- Halozyme Therapeutics, Inc. HALO
- ImmunityBio, Inc. IBRX
- Iovance Biotherapeutics, Inc. IOVA
- Lexicon Pharmaceuticals, Inc. LXRX
- Madrigal Pharmaceuticals, Inc. MDGL
- Mirum Pharmaceuticals, Inc. MIRM
- Rhythm Pharmaceuticals, Inc. RYTM
- SpringWorks Therapeutics, Inc. SWTX
- Tarsus Pharmaceuticals, Inc. TARS
- TG Therapeutics, Inc. TGTX
- Vericel Corporation VCEL
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | May 14, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 15, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 17, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 11, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Syndax Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Syndax Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
219 figures on this page: 215 cited to the filing that reported them, 4 calculated from figures it prints.
215 cited to the filing
4 calculated from the filing
Documents cited
- 0001193125-26-197859CEO Pay Ratio · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · and 2 more sections
- 0000950170-25-073555Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-25-048472Summary Compensation Table
- 0000950170-24-060462Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-040099Summary Compensation Table
- 0000950170-23-022802Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-22-019515
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Syndax Pharmaceuticals executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/SNDX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Syndax Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Syndax Pharmaceuticals discloses
The companies named in SNDX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}